Clinical Trial Update: TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating transarterial chemoembolization plus tislelizumab, lenvatinib, and carvedilol for unresectable hepatocellular carcinoma with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cirrhosis
• Portal Hypertension

Drugs mentioned

• Coreg (carvedilol)
• LENVIMA (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tongji Hospital | Conditions: HCC, Liver Cirrhosis | Phase 2 | Status: NOT_YET_RECRUITING